Related Experiment Video
Updated: Feb 9, 2026

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo
Published on: April 6, 2022
Identification of Compounds That Decrease Glioblastoma Growth and Glucose Uptake in Vitro
Catherine J Landis1, Sixue Zhang2, Gloria A Benavides3
1Department of Cell, Developmental and Integrative Biology , University of Alabama at Birmingham , Birmingham , Alabama , United States.
Abstract:
Tumor heterogeneity has hampered the development of novel effective therapeutic options for aggressive cancers, including the deadly primary adult brain tumor glioblastoma (GBM). Intratumoral heterogeneity is partially attributed to the tumor initiating cell (TIC) subset that contains highly tumorigenic, stem-like cells. TICs display metabolic plasticity but can have a reliance on aerobic glycolysis. Elevated expression of GLUT1 and GLUT3 is present in many cancer types, with GLUT3 being preferentially expressed in brain TICs (BTICs) to increase survival in low nutrient tumor microenvironments, leading to tumor maintenance. Through structure-based virtual screening (SBVS), we identified potential novel GLUT inhibitors. The screening of 13 compounds identified two that preferentially inhibit the growth of GBM cells with minimal toxicity to non-neoplastic astrocytes and neurons. These compounds, SRI-37683 and SRI-37684, also inhibit glucose uptake and decrease the glycolytic capacity and glycolytic reserve capacity of GBM patient-derived xenograft (PDX) cells in glycolytic stress test assays. Our results suggest a potential new therapeutic avenue to target metabolic reprogramming for the treatment of GBM, as well as other tumor types, and the identified novel inhibitors provide an excellent starting point for further lead development.
Insights
Novel GLUT inhibitors were identified to target glioblastoma (GBM) tumor-initiating cells. These compounds reduce glucose uptake and GBM cell growth, offering a potential new therapeutic strategy for aggressive brain cancers.
Area of Science:
- Oncology
- Cancer Metabolism
- Neuro-oncology
Background:
- Tumor heterogeneity in glioblastoma (GBM) hinders effective therapies.
- Brain tumor-initiating cells (BTICs) drive GBM growth and exhibit metabolic plasticity.
- GLUT3 is upregulated in BTICs, supporting survival in nutrient-poor environments.
Purpose of the Study:
- To identify novel inhibitors targeting glucose transporter 3 (GLUT3) in GBM.
- To evaluate the efficacy of identified inhibitors against GBM cells and BTICs.
- To explore targeting metabolic reprogramming as a therapeutic strategy for GBM.
Main Methods:
- Structure-based virtual screening (SBVS) was employed to identify potential GLUT inhibitors.
- In vitro assays assessed the impact of compounds on GBM cell growth and glucose uptake.
- Glycolytic stress tests were performed on patient-derived xenograft (PDX) cells.
Main Results:
- Two novel compounds, SRI-37683 and SRI-37684, were identified through SBVS.
- These compounds selectively inhibited GBM cell growth with minimal toxicity to normal cells.
- Inhibition of glucose uptake, glycolytic capacity, and reserve capacity was observed in GBM PDX cells.
Conclusions:
- Targeting GLUT3 offers a promising therapeutic avenue for glioblastoma.
- Novel GLUT inhibitors demonstrate potential for treating GBM and other cancers.
- SRI-37683 and SRI-37684 serve as valuable lead compounds for further drug development.
Related Concept Videos
Decreasing Function
Decreased Body Temperature
Decreased pulse rate
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
Glucose Homeostasis: Regulation of Blood Glucose
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
Coordination Compounds and Nomenclature
Molecules and Compounds

